[1] Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, Von Deimling A. (2016) WHO classification of tumours of the central nervous system[M]. 4th ed. Lyon:IARC Press, 2016:57-59.
[2] Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, Perry A. Diffuse midline gliomas with histone H3-K27M mutation:a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations[J]. Brain Pathol, 2016, 26:569-580.
[3] Fisher PG, Breiter SN, Carson BS, Wharam MD, Williams JA, Weingart JD, Foer DR, Goldthwaite PT, Tihan T, Burger PC. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities[J]. Cancer, 2000, 89:1569-1576.
[4] Kramm CM, Butenhoff S, Rausche U, Warmuth-Metz M, Kortmann RD, Pietsch T, Gnekow A, Jorch N, Janssen G, Berthold F, Wolff JE. Thalamic high-grade gliomas in children:a distinct clinical subset[J]? Neuron Oncol, 2011, 13:680-689.
[5] Ye H, He P, Sun YH, Guan H, Xia J. Diffuse midline gliomas with histone H3-K27M mutation:a study of four cases and literature review[J]. Ying Xiang Zhen Duan Yu Jie Ru Fang She, 2018, 27:380-383.[叶海, 何品, 孙艳花, 关弘, 夏军. 弥漫性中线胶质瘤伴H3K27M突变四例报告并文献复习[J]. 影像诊断与介入放射, 2018, 27:380-383.]
[6] Aboian MS, Solomon DA, Felton E, Mabray MC, Villanueva-Meyer JE, Mueller S, Cha S. Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation[J]. Am J Neuroradiol, 2017, 38:795-800.
[7] Herrlinger U, Jones DT, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G. Gliomatosis cerebri:no evidence for a separate brain tumor entity[J]. Acta Neuropathol, 2016, 131:309-319.
[8] Bechet D, Gielen GG, Korshunov A, Pfister SM, Rousso C, Faury D, Fiset PO, Benlimane N, Lewis PW, Lu C, David Allis C, Kieran MW, Ligon KL, Pietsch T, Ellezam B, Albrecht S, Jabado N. Specific detection of methionine 27 mutation in histone 3 variants (H3-K27M) in fixed tissue from high-grade astrocytoma[J]. Acta Neuropathol, 2014, 128:733-741.
[9] Hochart A, Escande F, Rocourt N, Grill J, Koubi-Pick V, Beaujot J, Meignan S, Vinchon M, Maurage CA, Leblond P. Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma[J]. Ann Clin Transl Neurol, 2015, 2:439-443.
[10] Orillac C, Thomas C, Dastagirzada Y, Hidalgo ET, Golfinos JG, Zagzag D, Wisoff JH, Karajannis MA, Snuderl M. Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation[J]. Acta Neuropathol Commun, 2016, 4:84.
[11] Yuen BT, Knoepfler PS. Histone H3.3 mutations:a variant path to cancer[J]. Cancer Cell, 2013, 24:567-574.
[12] Lewis PW, Müller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, Garcia BA, Muir TW, Becher OJ, Allis CD. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma[J]. Science, 2013, 340:857-861.
[13] Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, Sarkaria J, Zhang Z. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression[J]. Genes Dev, 2013, 27:985-990.
[14] Nikbakht H, Panditharatna E, Mikael LG, Li R, Gayden T, Osmond M, Ho CY, Kambhampati M, Hwang EI, Faury D, Siu A, Papillon-Cavanagh S, Bechet D, Ligon KL, Ellezam B, Ingram WJ, Stinson C, Moore AS, Warren KE, Karamchandani J, Packer RJ, Jabado N, Majewski J, Nazarian J. Spatial and temporal homogeneity of driver mutations in diffuse intrinsicpontine glioma[J]. Nat Commun, 2016, 7:11185.
[15] Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, Bison B, Claviez A, van Vuurden DG, von Bueren AO, Gessi M, Kühnle I, Hans VH, Benesch M, Sturm D, Kortmann RD, Waha A, Pietsch T, Kramm CM. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location[J]. Neuro Oncol, 2018, 20:123-131.
[16] Pagès M, Beccaria K, Boddaert N, Saffroy R, Besnard A, Castel D, Fina F, Barets D, Barret E, Lacroix L, Bielle F, Andreiuolo F, Tauziède-Espariat A, Figarella-Branger D, Puget S, Grill J, Chrétien F, Varlet P. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade Ⅰ ganglioglioma[J]. Brain Pathol, 2018, 28:103-111.
[17] Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hütt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma[J]. Nat Med, 2015, 21:555-559.
[18] Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, Solomon D, Mueller S, Paris PL, Zhang Z, Petritsch C, Gupta N, Waldman TA, James CD. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma[J]. Nat Med, 2014, 20:1394-1396. |